Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18515814 | 0.90 | OPRD1 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4PPID | |
| SCHEMBL18429328 | 0.90 | OPRD1 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4PPID | |
| SCHEMBL24191552 | 0.81 | F2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4F2 | |
| SCHEMBL18515815 | 0.80 | OPRM1 (0.52) | PPIDCTSS | |
| SCHEMBL3860594 | 0.77 | REN (0.52) | CTSS | |
| SCHEMBL3860587 | 0.77 | REN (0.52) | CTSS | |
| SCHEMBL2586349 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4QRFPR | |
| SCHEMBL2586350 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4QRFPR | |
| SCHEMBL24191455 | 0.77 | CTSS (0.55) | CTSSCTSKQRFPR | |
| SCHEMBL24191702 | 0.77 | LTA4H (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20150241443-A1 | MASS SPECTROMETRIC QUANTITATION | ELECTROPHORETICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | CHRNB2 2880/4885CHRNB4 3787/4885CHRNA3 3744/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | CHRNB2 2880/4885CHRNB4 3787/4885CHRNA3 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.